

प्रेषक,

अमित मोहन प्रसाद,
प्रमुख सचिव,
उत्तर प्रदेश शासन।

सेवा में,

महानिदेशक,
चिकित्सा एवं स्वास्थ्य सेवायें,
उत्तर प्रदेश।

चिकित्सा अनुभाग-5

लखनऊ; दिनांक: 16 अप्रैल, 2020

विषय:- कोविड-19 के परीक्षण हेतु CBNAAT एवं TRUENAT के उपयोग के संबंध में।
महोदय,

कृपया उपर्युक्त विषय के संबंध में संयुक्त सचिव, भारत सरकार, स्वास्थ्य एवं परिवार कल्याण मंत्रालय, नई दिल्ली के पत्र संख्या-05/2020/कोविड-19-ई0आर0एच0एस0पी0पी0, दिनांक 14.04.2020 (प्रति संलग्न) का अवलोकन करने का कष्ट करें, जिसके माध्यम से अवगत कराया गया है कि संपूर्ण देश में COVID-19 परीक्षण क्षमता को बढ़ाने में मदद करने के लिए राष्ट्रीय क्षय रोग उन्मूलन कार्यक्रम अंतर्गत CBNAAT के साथ-साथ TRUENAT का उपयोग किए जाने हेतु TRUENAT COVID-19 के चिप्स (Trunet Beta COV) और CBNAAT COVID-19 के कार्ट्रिज (Xpert Xpress SARS-CoV-2) के क्रय आदेश निर्गत किए गये हैं।

2- इस संबंध में मुझे यह कहने का निदेश हुआ है कि कोविड-19 के परीक्षण हेतु CBNAAT एवं TRUENAT के उपयोग के संबंध में निम्न बिन्दुओं पर तत्काल कार्यवाही सुनिश्चित कराने का कष्ट करें :-

- (1) प्रदेश में CBNAAT/TRUENAT प्लेटफार्म की उपलब्धता का आंकलन किया जाय।
- (2) लॉकडाउन अवधि में परीक्षण/चिन्हित स्थलों तक मशीनों और चिप्स के परिवहन के लिए आवश्यक लॉजिस्टिक सहायता प्रदान करायी जाय।
- (3) CBNAAT cartridges दिनांक 18 अप्रैल, 2020 तथा TRUENAT Chips की आपूर्ति दिनांक 25.04.2020 से होना संभावित है अतः COVID-19 के परीक्षण के लिए चिन्हित किए गए CBNAAT और TRUENAT स्थलों/जनपदों में पर्याप्त तकनीकी स्टाफ की उपलब्धता सुनिश्चित की जाय।
- (4) प्रत्येक संबन्धित तकनीकी स्टाफ/लैब स्टाफ को मशीन सुगमतापूर्वक संचालन हेतु जूम प्लेटफार्म पर निर्धारित आनलाइन प्रशिक्षण में समय से प्रतिभाग कराया जाय।
- (5) भारत सरकार से आपूर्ति प्राप्त होने से पूर्व समस्त CBNAAT/TRUENAT परीक्षण स्थलों का पंजीकरण आई0सी0एम0आर0 के पोर्टल पर कराकर यूजर आई0डी0 एवं पासवर्ड प्राप्त किया जाय।
- (6) COVID-19 अंतर्गत उपलब्ध रिपोर्टिंग प्रारूप से संरेखित रिपोर्टिंग प्रारूप तैयार किया जाय।

3- मुझे यह भी कहने का निदेश हुआ है कि उपरोक्त कार्यों के क्रियान्वयन/अनुश्रवण एवं मूल्यांकन/रिपोर्टिंग आदि हेतु एतद्वारा महानिदेशक, चिकित्सा एवं स्वास्थ्य सेवायें की अध्यक्षता में एक दल का गठन किया जाता है:-

1. डा0 संतोष गुप्ता, राज्य क्षय रोग नियंत्रण अधिकारी, लखनऊ।
2. डा0 मोईज अहमद, इपिडिमियोलॉजिस्ट, लखनऊ।
3. श्री अश्वनी कुमार पंकज, तकनीकी अधिकारी।

उपरोक्त बिन्दुओं को संज्ञान में लेते हुए भारत सरकार के पत्र में दिए गये लिंक <https://icmr.nic.in/content/covid-19> से आवश्यक प्रपत्र डाउनलोड करते हुए तत्काल ससमय आवश्यक कार्यवाही सुनिश्चित करते हुए कृत कार्यवाही से शासन को भी अवगत कराया जाय।

संलग्नक: यथोपरि।

भवदीय,


15.4.20

(अमित मोहन प्रसाद)
प्रमुख सचिव।


संख्या-872 (1)/पांच-5-2020, तद्दिनांक


प्रतिलिपि निम्नलिखित को सूचनार्थ एवं आवश्यक कार्यवाही हेतु प्रेषित:-

1. निजी सचिव, प्रमुख सचिव/सचिव/विशेष सचिव, चिकित्सा, स्वास्थ्य एवं परिवार कल्याण, उ0प्र0 शासन लखनऊ।
2. अधिशासी निदेशक, उ0प्र0 तकनीकी सहयोग इकाई, लखनऊ।
3. निदेशक, संचारी रोग, चिकित्सा, स्वास्थ्य एवं परिवार कल्याण, उत्तर प्रदेश।
4. स्टेट सर्विलान्स अधिकारी, उत्तर प्रदेश।
5. स्टेट क्षय रोग नियंत्रण अधिकारी।
6. गार्ड फाइल।

संलग्नक: यथोपरि।

आज्ञा से,


15/04/2020
(वेद प्रकाश राय)
अनु सचिव।


15/04/2020
2020/4
15.04.2020

संख्या - 872/पांच - 5-2020



विकास शील
संयुक्त सचिव
VIKAS SHEEL
Joint Secretary



भारत सरकार
स्वास्थ्य एवं परिवार कल्याण मंत्रालय
निर्माण भवन, नई दिल्ली - 110011
Government of India
Ministry of Health & Family Welfare
Nirman Bhavan, New Delhi -110011
Tel. : 011-23063506
: 011-23061481 (T/F)
E-mail : sheelv@nic.in

D.O. letter no. 05/2020/COVID-19-ERHSPP
Dated: 14th April 2020

Dear Sir/Madam,

As you are aware, Central TB Division, MoHFW, GOI has placed purchase orders for Truenat COVID-19 chips (*Truenat beta COV*) and CBNAAT COVID-19 cartridges (*Xpert Xpress SARS-CoV-2*) to help ramping up the COVID-19 testing capacity across the country, using CBNAAT as well as Truenat platforms available under National Tuberculosis Elimination Programme.

CBNAAT COVID-19 cartridges (*Xpert Xpress SARS-CoV-2*)

This is to inform that as per the guidance issued by ICMR since *Xpert Xpress SARS-CoV-2* test is US FDA (EUA) approved, it does not require further approval from ICMR. Sample processing for COVID-19 testing requires Biosafety Level 2 (BSL 2) or higher facility. Currently, under NTEP there are about 135 GeneXpert machines collocated with BSL 2 facilities. These sites can be used for COVID-19 testing. A list of such sites is enclosed at Annexure 1. The tranche wise consignee list and quantity of cartridges (*Xpert Xpress SARS-CoV-2*) ordered by CTD is enclosed at Annexure 2. Technical specifications and kit content of *Xpert Xpress SARS-CoV-2* is enclosed at Annexure 3

Truenat COVID-19 Chips (*Truenat beta COV*)

1. *Truenat beta COV* test on *Truelab* workstation has been validated and recommended by ICMR as a screening test. Guidance on the use of *Truenat beta COV* provided by ICMR is available on ICMR website <https://icmr.nic.in/content/covid-19> (copy enclosed at Annexure 4). Technical specifications and kit content of *Truenat beta COV* is enclosed at Annexure 5.
2. As indicated in the guidance document provided by ICMR, States may appoint a core team of experts for assessing facilities with the *Truelab* workstations for feasibility of initiating the COVID-19 testing. State-wise numbers of existing 367 Truenat machines and tranche wise numbers of additional 500 Truenat machines is enclosed at Annexure 6. The State wise distribution of the 500 additional Truenat machines has been worked out in consultation with ICMR.
3. Tranche wise quantity of chips (*Truenat beta COV*) for existing 367 and additional 500 Truenat machines is enclosed at Annexure 7.
4. The State Government is requested to provide the necessary logistics support for transportation of machines and chips up to the testing sites, especially during the lockdown period.

एड्स - जानकारी ही बचाव है
Talking about AIDS is taking care of each other
www.mohfw.nic.in

अपेक्ष
15/04/2020

patient undergoing treatment/intervention or any of his/her family member. However, in case there are other health complications not associated with COVID-19, DCH should be able to deploy appropriate health specialist. For an Ayushman patient, the cost will be covered and paid for by the Scheme. For a non-Ayushman patient, with regards to the non-COVID-19 complications, cost will be borne by the patient. *at Ayushman rates*

- (ii) The treatment protocol will be followed as per the COVID-19 guidelines and protocol issued by the DoHFW from time to time.
 - (iii) The treatment rate will include the following:
 - a. Registration Charges
 - b. Bed charges, Nursing charges,
 - c. Surgeons, Anesthetists, Consultants fees etc.
 - d. Anesthesia, Blood Transfusion, Oxygen, O.T. Charges, Cost of Surgical Appliances etc,
 - e. Medicines and Drugs,
 - f. Food to patient
 - g. Bio-waste disposal
 - h. Security and Safety of Premises
 - i. Any other expenses related to the treatment of the patient in the DCH under the scheme.
 - j. Cost of transportation of patient samples and test results to and fro the Govt-approved testing labs
6. The DCH shall ensure that medical treatment/facility under this agreement should be provided to the patient with all due care and accepted standards. DCH will ensure that it is COVID-ready as per COVID-statutory laws and associated protocol and guidelines, and that all requisite medical and ancillary staff is deployed for patient treatment. The hospital premises and its vicinity need to be sanitized as per the Govt protocol. COVID-19 IEC (modules developed by Government) shall have to be put in places by DCH.
7. DCH agrees to provide treatment to all referred COVID-10 patients, as per specified Govt Rates. For patients entitled under Ayushman Bharat and Mukhyamantri Jan Arogya Abhiyan (MMJAA), DCH will have to book the patient through the Ayushman software and will be paid as per the prevailing PMJAY. For non-Ayushman patients, payment will flow directly from Department of Health and Family Welfare, GoUP as per the payment norms in GO 2018/96/5-1-2018-5(18)/2018 dated 21 May 2018
8. The DCH shall allow Nodal District Covid-19 Committee (NDCC) to visit the isolation as well as treatments wards in the DCH. NDCC shall not interfere with the medical team of the DCH, however NDCC reserves the right to discuss the treatment plan with treating doctor. NDCC will help DCH in communication with the district administration for any potential gaps in the treatment of the corona patient.
- 5

5. It may also be noted that though the new Truenat machines are being procured based on the needs identified for TB testing in the States/UTs, in view of the COVID-19 emergency, the States have full flexibility in deciding the deployment of the new machines as per testing needs for COVID-19. The Truenat machines can subsequently be redeployed according to the plans prepared for TB testing.

Supply of CBNAAT cartridges and Truenat Chips

The supply of CBNAAT cartridges is likely to start from 18th April 2020 and Truenat chips for existing machines is likely to start from 25th April 2020. Accordingly, it is requested that the CBNAAT and Truenat sites identified for COVID-19 testing may be prepared with the laboratory staff of these sites suitably trained.

Training of Laboratory staff

Virtual training schedule of lab staff on Zoom platform for conducting the COVID-19 Testing on CBNAAT machine has been communicated to the States (copy enclosed at Annexure 8). Training schedule for COVID-19 Testing on Truenat machine will also be shared shortly.


Mandatory Registration in ICMR Portal

1. Registration of all the CBNAAT\Truenat testing sites may be ensured on ICMR Portal before the Truenat chips and CBNAAT cartridges supplies start. States may contact ICMR focal points for registration and uploading the results in the ICMR portal. Each laboratory initiating COVID-19 testing must register on the ICMR portal and get a username and password. Data entry should be ensured daily on a real-time basis.
2. As the details of sample collection centers sending the samples for RTPCR testing are being collected by you to enable the App of Samples Reference Form (SRF), I request you to also map the collection Centres to these CBNAAT / Truenat testing Centres so as to capture the results in ICMR portal.
3. Contact point for registration and technical issues at ICMR is Dr. Harpreet Singh (hsingh@bmi.icmr.org.in) and Dr. Ira Praharaj (praharaj.ira@icmr.gov.in). For logistics related issues, you may contact Dr. Nishant Kumar (kumarn@rntep.org) at CTD.

warm regards and best wishes

Encl: As above

Yours sincerely


(Vikas Sheel) 15/04/20

To,

Additional Chief Secretary/Pr. Secretary/Secretary - Health, All States/UTs